Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?

BACKGROUND: Trastuzumab was approved in the United Kingdom for adjuvant treatment of human epidermal growth factor receptor 2 (HER2)+ breast cancer in 2006 at significant economic cost and with limited evidence in smaller T1N0 tumours. The South East Wales Cancer Network covers a population of 1 420...

Descripción completa

Detalles Bibliográficos
Autores principales: Webster, R M, Abraham, J, Palaniappan, N, Caley, A, Jasani, B, Barrett-Lee, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251855/
https://www.ncbi.nlm.nih.gov/pubmed/22108523
http://dx.doi.org/10.1038/bjc.2011.506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251855/
https://www.ncbi.nlm.nih.gov/pubmed/22108523
http://dx.doi.org/10.1038/bjc.2011.506

Ejemplares similares